Case reportJanus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata
Under a Creative Commons license
open access
Key words
alopecia areata
atopic dermatitis
autoimmunity
Down syndrome
eczema
interferon
Janus kinase inhibition
tofacitnib
vitiligo
Xeljanz
trisomy 21
Abbreviations used
AA
alopecia areata
DS
Down syndrome
IFN
interferon
JAK
Janus kinase
STAT
signal transducer activator of transcription
T21
trisomy 21
Cited by (0)
Funding sources: University of Colorado Linda Crnic Institute for Down Syndrome, Global Down Syndrome Foundation, and the Anna and John J. Sie Foundation.
Conflicts of interest: Dr Cory Dunnick discloses that she is the principal investigator for 2 clinical trials with Pfizer using an investigational JAK inhibitor to treat alopecia areata. All clinical trial reimbursement is paid to the University of Colorado. The rest of the authors have no conflicts to disclose.
© 2019 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.